Glucose DEXCOM announced that it has received a FDA clearance for the G7 15 -day continuous glucose monitoring (CGM) system for people over 18 years of age with type 1, type 2 and gestational diabetes.
The G7 15 Day, which is scheduled to be released in the second half of this year, has 15.5 days wear time (According to the company, it includes a 12 -hour grace period and is 15% longer than the Dexcom G7.
The new system sends real -time glucose information to the DEXCOM G7 app or receiver every 5 minutes through the sensor without a finger stick or scan.
The system has a whole The average absolute difference is 8.0%. According to the NIH National Medical Library, MARD Parameters used to characterize Measurement performance of the CGM system.
The DEXCOM G7 is waterproof and hands -free Connect the sensor directly to Apple Watch.
It also has an automated activity logging feature that allows the end user to enter meals and drug information.
The Dexcom CLARITY mobile app is compatible with smartphones or computers and provides a means of sharing not only glucose patterns and statistics, but also the caregiver and the family and glucose data with the family.
Meanwhile, the company works with insulin pump partners to ensure that the Dexcom G7 15 days is compatible with the automatic insulin delivery system.
Jake Leach, vice president and chief operating officer of Dexcom, said, “The approval of the DEXCOM G7 15 days indicates another major innovation of Dexcom.
“I am proud to have provided the longest wearable and the most accurate CGM while listening to the user’s demands.
Greater trend
March, Cardiometabolic Diagnostics Company NANOWEAR presented Dexcom and license and data partnerships to integrate glucose data from Dexcom and Dexcom G7 into simpler nanotechnical available wearables.
Nanowear offers home -based AI support digital diagnosis for heart metabolism. The company’s FDA-CLEARED SIMPLESENSE wearable reads the vitality of patients, including respiratory speed, heart rate, blood pressure, physical activity and lung.
In 2024, Dexcom earned $ 75 million We have established a strategic partnership that enables two -way data flow between strategic investments in health tracking maker OURA and Dexcom’s CGM and our Ring.
Dexcom donated $ 75 million to OURA’s series D funding round, bringing OURA’s evaluation to more than $ 5 billion.
Through Partnerships, users of the two companies were able to access glucose data from the Dexcom glucose bio sensor and sleep, heart health, stress, important signs and activity data of the DEXCOM apps and the apps of OURA.
In the same year, DEXCOM expanded Diabetes Management function provided a direct connection with Apple Watch for the G7 CGM system through a dedicated Bluetooth connection.
This feature allows users to check the glucose readings in real time without the iPhone.
2022 The FDA has been removed by the DEXCOM G7 CGM. This model was for individuals with two years of age with all types of diabetes.
Other companies in the CGM space include: Abbott announced that CGM System Lingo can be purchased in the United States without prescription in 2024.
Lingo includes Bio sensors and mobile apps based on Abbott’s freestyle Libre continuous glucose monitoring technology. This system is a bio -wide product for people over 18 years of age who do not take insulin.
The system provides personal insights and coaching to track glucos in real time, build healthy habits for end users, retrain metabolism, and improve overall health.
Same year, Medtronic has been approved for FDA for Simplera CGM, the company’s first disposable All-in-One CGM, which is half the size of the previous Medtronic CGM.
The SIMPLERA platform features a company’s CGM form factor and includes a Simplera CGM designed to be used as part of the SMART MDI system designed to integrate with the Inpen Smart Insulin Pen and the simple 780g insulin system.
Last year, Medtronic Due to the potentially shortened battery life of the pump, we voluntarily recalled the at least 600 and 700 series insulin pumps.
The company informed the customer that the company must monitor the built -in alarm and alert of the minimalized pump to track the battery status and change the battery life of the pump.
